"Designing Growth Strategies is in our DNA"

Allergy Immunotherapy Market Size, Share and Global Trend By Treatment (Subcutaneous Immunotherapy, Sublingual Immunotherapy), By Allergy (Allergic Rhinitis, Asthma, Food Allergy, Drug Allergy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online Pharmacies), and Geography Forecast till 2026

Region : Global | Published Date: Upcoming | Report ID: FBI100727| Status : Upcoming



According to WHO (World Health Organisation), 20-50% of the global population is suffering from allergies in 2017. According to FARE (Food Allergy Research & Association), approximately 15 million people in the United States have food allergies; 4% of which is seen in pediatrics and more than 60% in adults. Allergy is hypersensitivity of the body’s immune system towards different substances such as particular food, pollen, fur or dust. There are different types of allergies such as food, dust, pollens, latex, drugs, and others. Allergy immunotherapy is a form of treating allergies by exposing the body to allergens in small quantities for developing antibodies towards the allergens. Constant and small exposure to specific allergens by immunotherapy helps the body to cope with the presence of allergens, leading to efficient and timely treatment of allergy.

The rise in industrialization and population, advancement in the treatment and medicine, and introduction to new immunotherapeutic drugs are the major driving force for the global allergy immunotherapy market. Recent regulatory approvals such as oral dissolvable tablets are further augmented to raise the market share of the global allergy immunotherapy market.

To get information on various segments, share your queries with us

The factor that is expected to inhibit the growth of the market is limited applications such as immunotherapy does not work on all the type of allergies, insect venom allergies cannot be basically controlled by immunotherapy.

Key Players Covered

Some of the major companies that are present in the global allergy immunotherapy market are Stallergenes Greer, ALK, Allergy Therapeutics, Merck KGaA, HAL Allergy B.V., Biomay AG, Anergis, Aimmune Therapeutics., Circassia, DBV Technologies and others.




By Treatment

· Subcutaneous Immunotherapy (SCIT)

· Sublingual Immunotherapy (SLIT)

By Allergy

· Allergic Rhinitis

· Asthma

· Food Allergy

· Drug Allergy

· Others

By Distribution Channel

· Hospital Pharmacies

· Retail Pharmacies and Drug Stores

· Online Pharmacies

By Geography

· North America (USA and Canada)

· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

· Latin America (Brazil, Mexico and Rest of Latin America)

· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


At present, SCIT (subcutaneous Immunotherapy) is an extensively used and effective form of Allery immunotherapy. The subcutaneous immunotherapy segment dominated the global immunotherapy market in 2018. This segment is projected to expand rapidly and gain market share during the forecast period.

Key Insights

  • Pipeline analysis
  • Regulatory scenario for key countries
  • Reimbursement scenario for key countries
  • Key mergers and acquisitions
  • Prevalence of diseases being treated by currently approved allergy immunotherapy products in key countries

  • Regional Analysis

The global allergy immunotherapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for allergy immunotherapy at present and they are expected to account for a large proportion of the market in the forecast period as well. Europe reported to share for a second largest share of the global allergy immunotherapy market due to high awareness, increase in funding for research and grants, medical reimbursement policies, the rise in allergic population, and others. The global allergy immunotherapy market in Asia Pacific considered to be fastest growing market, attributed to an increase in the huge allergic patient pool during the forecast period.

Key Industry Developments

  • In January 2019, Sandoz Inc. announced the US market introduction of SYMJEP (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1).
  • In June 2018, Aimmune Therapeutics, declared phase 3 trial results for AR101, an oral immunotherapy medication focused on peanut allergies, have met all the end points required by the U.S. Food and Drug Administration (FDA)
  • In June 2018, Torii Pharmaceutical Co., Ltd., launched CEDARCURE Japanese Cedar Pollen sublingual tablets an allergen immunotherapy tablet for Japanese Cedar Pollinosis

Allergy Immunotherapy Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2018
  • 2014-2017


  • 4850

Healthcare Clients

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.